Editor's Desk

Business News

AstraZeneca Strikes ‘Historic’ Drug Pricing Deal with US Government, Commits $50 Billion to US Manufacturing

AstraZeneca

AstraZeneca has announced a landmark agreement with the US government to significantly cut the cost of prescription medicines for millions of American patients via the Most-Favored-Nation (MFN) drug pricing model. The deal includes up to 98% discounts on key respiratory drugs for direct patient purchases and a $50 billion commitment to US manufacturing and R&D, securing a three-year exemption from threatened tariffs.

Business News

Amgen to Bolster U.S. Innovation with Over $600 Million Investment in New California Research Center

amgen

Biotechnology giant Amgen is investing over $600 million to build a new research and development hub in Southern California. The cutting-edge facility will bring together top scientific minds to advance the creation of new medicines and is expected to generate hundreds of jobs, reinforcing the company’s commitment to U.S.-based innovation.

Clinical Trials News Weight-loss Drugs

Lilly’s Oral GLP-1 Orforglipron Shows Significant Weight Loss in Phase 3 ATTAIN-1 Trial

Eli Lilly and Company

Eli Lilly and Company announced that its investigational oral GLP-1 receptor agonist, orforglipron, delivered an average weight loss of 27.3 lbs in the Phase 3 ATTAIN-1 trial. The once-daily pill demonstrated a safety profile consistent with existing injectable GLP-1 therapies and also showed improvements in cardiovascular risk factors.

Business Healthcare & Pharmaceuticals News

Eli Lilly Reports Strong Q2 2025 Financial Results with 38% Revenue Growth

Eli Lilly and Company

Eli Lilly and Company reported strong second-quarter 2025 financial results, with worldwide revenue increasing 38% to $15.56 billion. This growth was driven by a 42% increase in volume, particularly from the company’s key products Zepbound and Mounjaro. Reported earnings per share (EPS) for the quarter were $6.29, a 92% increase compared to the same period in 2024. Following these results, Lilly has raised its full-year 2025 revenue guidance to a range of $60.0 billion to $62.0 billion.